pegaptanib (Macugen)

a 28-base ribonucleic acid aptamer covalently linked to two branched 20-kD polyethylene glycol moieties to block the activity of extracellular VEGF, specifically the 165-amino-acid isoform (VEGF165); for treatment of neovascular age-related macular degeneration

Also Known As:

Networked: 246 relevant articles (42 outcomes, 55 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Adamis, Anthony P: 12 articles (01/2016 - 12/2004)
2.	Patel, Manju: 7 articles (10/2007 - 10/2005)
3.	Cunningham, Emmett T: 6 articles (04/2009 - 12/2004)
4.	Goldbaum, Mauro: 5 articles (12/2010 - 10/2005)
5.	Guyer, David R: 5 articles (04/2009 - 12/2004)
6.	Brown, Gary C: 4 articles (01/2012 - 01/2007)
7.	Ho, Allen C: 4 articles (01/2012 - 09/2007)
8.	Feucht, N: 3 articles (08/2016 - 06/2008)
9.	Ishibashi, Tatsuro: 3 articles (05/2015 - 09/2013)
10.	Yuzawa, Mitsuko: 3 articles (09/2014 - 04/2013)

Related Diseases

1.	Macular Degeneration (Age-Related Maculopathy) 07/01/2005 - "Pegaptanib was effective and safe without a dose-response relation in neovascular, age-related, macular degeneration." 10/01/2012 - "Treating early choroidal neovascularisation with pegaptanib sodium in patients with neovascular age-related macular degeneration: findings of the PERSPECTIVES study." 02/09/2010 - "Newly diagnosed exudative age-related macular degeneration treated with pegaptanib sodium monotherapy in US community-based practices: medical chart review study." 07/01/2008 - "[Pegaptanib sodium one-year treatment study for neovascular age-related macular degeneration]." 09/01/2007 - "Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration."
2.	Choroidal Neovascularization 09/01/2007 - "In the combined cohorts, 147 subjects with any angiographic subtype of subfoveal choroidal neovascularization secondary to AMD and best-corrected visual acuities (VAs) in the study eye of 20/40 to 20/320 and in the fellow eye of 20/800 or better received pegaptanib sodium. " 04/01/2013 - "To evaluate ophthalmologic outcomes 1 year after intravitreal pegaptanib sodium injection in patients with myopic choroidal neovascularization (CNV). " 04/01/2013 - "[Intravitreal pegaptanib sodium for myopic choroidal neovascularization: 1 year results of a prospective pilot study]." 06/01/2008 - "This paper reports clinical experience with pegaptanib sodium for the treatment of occult or minimally classic choroidal neovascularization (CNV) due to AMD. " 09/01/2007 - "Six eyes from six patients who developed RPE tears while undergoing treatment with pegaptanib for AMD-related fibrovascular pigment epithelial detachment (PED) and occult choroidal neovascularization (CNV) were identified retrospectively. "
3.	Macular Edema 01/01/2015 - "Pegaptanib has been shown to be effective in treating diabetic macular edema (DME). " 01/01/2013 - "Pegaptanib proved to be efficacious and safe for the treatment of diabetic macular edema throughout the 12-month followup. " 09/01/2014 - "[Japan phase 3 study of pegaptanib sodium in patients with diabetic macular edema]." 01/01/2014 - "The purpose of this study was to evaluate the safety and tolerability of pegaptanib in patients with diabetic macular edema. " 01/01/2014 - "An open-label, one-year, noncomparative study to evaluate the safety and tolerability of intravitreal pegaptanib sodium in patients with diabetic macular edema."
4.	Retinal Vein Occlusion 07/01/2010 - "Pegaptanib for branch retinal vein occlusion." 04/01/2009 - "To assess the safety and efficacy of intravitreous pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO). " 01/01/2011 - "Pegaptanib sodium is a safe and efficacy treatment for macular edema secondary to branch retinal vein occlusion." 01/01/2011 - "Intravitreal pegaptanib for refractory macular edema secondary to retinal vein occlusion." 01/01/2010 - "Pegaptanib sodium for macular edema secondary to branch retinal vein occlusion."
5.	Corneal Neovascularization 06/01/2021 - "Effect of Topical Instillation of Pegaptanib Sodium Upon Inflammatory Corneal Neovascularization in Rabbits." 06/01/2014 - "The mouse model of suture-induced corneal neovascularization was used to assess the antihem- and antilymphangiogenic effect of topically applied pegaptanib. " 02/01/2008 - "Pretreatment with pegaptanib sodium appeared to decrease the efficacy of PDT-induced vessel regression in corneal neovascularization, and as such the enhanced efficacy over monotherapy when the agents were delivered simultaneously was not observed. " 06/01/2021 - "Conclusion: Topical instillation of 0.5% and 1.0% pegaptanib sodium diluted in 15 mL 0.5% carboxymethylcellulose sodium had no inhibitory effect on corneal neovascularization in this rabbit model." 01/01/2013 - "Comparison of subconjunctivally injected bevacizumab, ranibizumab, and pegaptanib for inhibition of corneal neovascularization in a rat model."

Related Drugs and Biologics

1.	pegaptanib (Macugen)
2.	Ranibizumab (Lucentis)
3.	Bevacizumab (Avastin)
4.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
5.	Retinaldehyde (Retinal)
6.	1-phenyl-3,3-dimethyltriazene (PDT)
7.	aflibercept
8.	Verteporfin (Visudyne)
9.	salicylhydroxamic acid (SHAM)
10.	bevasiranib

Related Therapies and Procedures

1.	Therapeutics
2.	Intravitreal Injections
3.	Injections
4.	Lasers (Laser)
5.	Light Coagulation